LIGIA CAMERA PIERROTTI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Fast Decrease of Humoral Response Against SARS-CoV-2 in A Kidney Transplant Cohort(2022) COSTA, Gisela Serra Rodrigues; MIRANDA, Lara Judith Cabral; BRINGEL, Eric Arcanjo; OTTO, Jose Junior; CENEVIVA, Carina; CORA, Aline Pivetta; SILVA, Luciane Carvalho Sarahyba; DIAS, Claudia Maria Meira; UDILOFF, Patricia Alves Santos; DAVID-NETO, Elias; PIERROTTI, Ligia Camera- Strongyloides infection screening in transplant candidates: What is the best strategy?(2023) GRYSCHEK, Ronaldo Cesar Borges; CORRAL, Marcelo Andreetta; SITTA, Renata Barnabe; GOTTARDI, Maiara; PIERROTTI, Ligia Camera; COSTA, Silvia Figueiredo; ABDALA, Edson; CHIEFFI, Pedro Paulo; PAULA, Fabiana Martins deBackground: The potential that Strongyloides stercoralis infection has to cause major morbidity and high mortality when the disseminated form occurs in transplant patients is of particular concern.Methods: In this study, the objective was to observe S. stercoralis infection in patients who are candidates for transplantation by using parasitological, serological, and molecular techniques and to propose an algorithm for the detection of that infection in transplant candidates.Results: By parasitological techniques, 10% of fecal samples were positive. Anti-Strongyloides antibodies immunoglobulin G were detected in 19.3% and 20.7% of patients by immunofluorescence assay and enzyme-linked immunosorbent assay, respectively. S. stercoralis DNA was observed in 17.3% of samples by conventional polymerase chain reaction and 32.7% of samples by quantitative polymerase chain reaction (qPCR).Conclusion: The set of results allows us to reinforce that a positive result by parasitological techniques and/or qPCR indicates that the specific treatment should be applied. However, the improvement of diagnostic techniques may suggest changes in the screening for strongyloidiasis in these patients. image
- Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae(2023) PEREZ-NADALES, Elena; FERNANDEZ-RUIZ, Mario; NATERA, Alejandra M.; GUTIERREZ-GUTIERREZ, Belen; MULARONI, Alessandra; RUSSELLI, Giovanna; PIERROTTI, Ligia Camera; FREIRE, Maristela Pinheiro; FALCONE, Marco; TISEO, Giusy; TUMBARELLO, Mario; RAFFAELLI, Francesca; ABDALA, Edson; BODRO, Marta; GERVASI, Elena; FARINAS, Maria Carmen; SEMINARI, Elena M.; CASTON, Juan Jose; MARIN-SANZ, Juan Antonio; GALVEZ-SOTO, Victor; RANA, Meenakshi M.; LOECHES, Belen; MARTIN-DAVILA, Pilar; PASCUAL, Alvaro; RODRIGUEZ-BANO, Jesus; AGUADO, Jose Maria; MARTINEZ-MARTINEZ, Luis; TORRE-CISNEROS, Julian; REIPI INCREMENT-SOT Study GrpWe aimed to compare the efficacy of ceftazidime-avibactam (CAZ-AVI) versus the best available therapy (BAT) in solid organ transplant (SOT) recipients with bloodstream infection caused by carbapenemase-producing Klebsiella pneumoniae (CPKP-BSI). A retrospective (2016-2021) observational cohort study was performed in 14 INCREMENT-SOT centers (ClinicalTrials.gov identifier: NCT02852902; Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL-or Carbapenemaseproducing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study). Outcomes were 14-day and 30-day clinical success (complete resolution of attributable manifestations, adequate source control, and negative follow-up blood cultures) and 30-day all-cause mortality. Multivariable logistic and Cox regression analyses adjusted for the propensity score to receive CAZ-AVI were constructed. Among 210 SOT recipients with CPKP-BSI, 149 received active primary therapy with CAZ-AVI (66/149) or BAT (83/ 149). Patients treated with CAZ-AVI had higher 14-day (80.7% vs 60.6%, P =.011) and 30 day (83.1% vs 60.6%, P = .004) clinical success and lower 30-day mortality (13.25% vs 27.3%, P =.053) than those receiving BAT. In the adjusted analysis, CAZ-AVI increased the probability of 14-day (adjusted odds ratio [aOR], 2.65; 95% confidence interval [CI], 1.036.84; P = .044) and 30-day clinical success (aOR, 3.14; 95% CI, 1.17-8.40; P = .023). In contrast, CAZ-AVI therapy was not independently associated with 30-day mortality. In the CAZ-AVI group, combination therapy was not associated with better outcomes. In conclusion, CAZ-AVI may be considered a first-line treatment in SOT recipients with CPKP-BSI.
conferenceObject Development of an Intelligent Digital Biosurveillance Platform(2022) ROZA, Bartira De Aguiar; SILVA, Vanessa Silva e; MENDES, Karina Dal Sasso; TREVISO, Patricia; THOME, Tadeu; GARCIA, Valter Duro; PIERROTTI, Ligia Camera; DIAS, Alvaro Machado; SCHIRMER, JanineconferenceObject Omicron COVID-19 in Kidney Transplant Recipients(2022) COSTA, Gisela Serra Rodrigues; REUSING, Jose Otto; FREIRE, Maristela Pinheiro; MOREIRA, Raquel Megale; LITVOC, Marcelo Nobrega; VENTURA, Carlucci; MACHADO, David; DAVID-NETO, Elias; PIERROTTI, Ligia CameraconferenceObject Prediction Model With Quantiferon-CMV for Clinically Significant Cytomegalovirus Event in Seropositive Kidney Transplant Recipients(2022) REUSING JUNIOR, Jose Otto; AGENA, Fabiana; CAMPANA, Gustavo A.; PIERROTTI, Ligia C.; DAVID-NETO, Elias- Transplantation in the Tropics: Lessons on Prevention and Management of Tropical Infectious Diseases(2015) PIERROTTI, Ligia C.; KOTTON, Camille N.Tropical infectious diseases (IDs) remain a rare complication in transplant recipients even in tropical settings, but this topic has become increasingly important during the last decade due to multiple factors. Interestingly, non-tropical countries report most of the experiences with tropical diseases. The reported experience from non-endemic regions, however, does not always reflect the experience of endemic areas. Most of the guidelines and recommendations in the literature may not be applicable in tropical settings due to logistical difficulties, cost, and lack of proven benefit. In addition, certain post-transplant prevention measures, as prophylaxis and reducing exposure risk, are not feasible. Nonetheless, risk assessment and post-transplant management of tropical IDs in tropical areas should not be neglected, and clinicians need to have a higher clinical awareness for tropical ID occurring in this population. Herein, we review the more significant tropical ID in transplant patients, focusing on relevant experience reported by tropical settings.
- Subtypes of Blastocystis sp. isolated in fecal samples from transplant candidates in Sao Paulo, Brazil(2020) SILVA, Maria do Rosario A.; MELO, Gessica B.; MALTA, Fernanda M.; ABDALA, Edson; COSTA, Silvia F.; PIERROTTI, Ligia C.; GONCALVES, Elenice M. N.; CASTILHO, Vera L. P.; CHIEFFI, Pedro P.; GRYSCHEK, Ronaldo C. B.; PAULA, Fabiana M.Blastocystis sp. is an intestinal protozoan commonly found in fecal samples of many animal species, including humans, but poorly studied in transplant candidates. The aim of this study was to evaluate the occurrence and molecular identification of Blastocystis sp. in fecal samples from transplant candidates. A polymerase chain reaction was performed using specific primers for Blastocystis ribosomal DNA. The DNA sequences obtained were aligned and compared with other sequences from the GenBank and MLST databases. The analyzed samples showed a positivity of 16% (24 of 150) for Blastocystis sp. The highest occurrence was observed in renal transplant candidates (31.4%), followed by hepatic transplant candidates (10.4%) and candidates for bone marrow transplantation (5.9%). Subtype (ST) 3 (45.8%) was the most prevalent among the isolates, followed by ST1 (375%), ST2 (12.5%), and ST7 (4.2%). This is the first study of molecular identification Blastocystis sp. in transplant candidates. Our results confirmed that ST3 was the most common subtype in transplant candidates and reinforce the importance of new studies to investigate of Blastocystis sp. in these patients. (C) 2019 Published by Elsevier Ltd on behalf of World Federation of Parasitologists.
- New Perspectives in Cytomegalovirus After Transplant: The Role of Immunosuppressant Management(2023) PIERROTTI, Ligia C.; CLEMENTE, Wanessa T.